166 related articles for article (PubMed ID: 17123821)
1. Design, synthesis, and antiproliferative and CDK2-cyclin a inhibitory activity of novel flavopiridol analogues.
Ahn YM; Vogeti L; Liu CJ; Santhapuram HK; White JM; Vasandani V; Mitscher LA; Lushington GH; Hanson PR; Powell DR; Himes RH; Roby KF; Ye Q; Georg GI
Bioorg Med Chem; 2007 Jan; 15(2):702-13. PubMed ID: 17123821
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and biological study of novel pyrido[2,3-d]pyrimidine as anti-proliferative CDK2 inhibitors.
Ibrahim DA; Ismail NS
Eur J Med Chem; 2011 Dec; 46(12):5825-32. PubMed ID: 22000924
[TBL] [Abstract][Full Text] [Related]
3. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects.
Kim KS; Sack JS; Tokarski JS; Qian L; Chao ST; Leith L; Kelly YF; Misra RN; Hunt JT; Kimball SD; Humphreys WG; Wautlet BS; Mulheron JG; Webster KR
J Med Chem; 2000 Nov; 43(22):4126-34. PubMed ID: 11063609
[TBL] [Abstract][Full Text] [Related]
4. 3-Amino-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: a new class of CDK2 inhibitors.
Pevarello P; Fancelli D; Vulpetti A; Amici R; Villa M; Pittalà V; Vianello P; Cameron A; Ciomei M; Mercurio C; Bischoff JR; Roletto F; Varasi M; Brasca MG
Bioorg Med Chem Lett; 2006 Feb; 16(4):1084-90. PubMed ID: 16290148
[TBL] [Abstract][Full Text] [Related]
5. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and molecular docking of novel pyrazolo[1,5-a][1,3,5]triazine derivatives as CDK2 inhibitors.
Oudah KH; Najm MAA; Samir N; Serya RAT; Abouzid KAM
Bioorg Chem; 2019 Nov; 92():103239. PubMed ID: 31513938
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, biological evaluation, and molecular docking studies of N-((1,3-diphenyl-1H-pyrazol-4-yl)methyl)aniline derivatives as novel anticancer agents.
Huang XF; Lu X; Zhang Y; Song GQ; He QL; Li QS; Yang XH; Wei Y; Zhu HL
Bioorg Med Chem; 2012 Aug; 20(16):4895-900. PubMed ID: 22819191
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors.
Baltus CB; Jorda R; Marot C; Berka K; Bazgier V; Kryštof V; Prié G; Viaud-Massuard MC
Eur J Med Chem; 2016 Jan; 108():701-719. PubMed ID: 26741853
[TBL] [Abstract][Full Text] [Related]
9. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis.
Patel V; Senderowicz AM; Pinto D; Igishi T; Raffeld M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS
J Clin Invest; 1998 Nov; 102(9):1674-81. PubMed ID: 9802881
[TBL] [Abstract][Full Text] [Related]
10. Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells.
Motwani M; Li X; Schwartz GK
Clin Cancer Res; 2000 Mar; 6(3):924-32. PubMed ID: 10741717
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors.
Ibrahim DA; El-Metwally AM
Eur J Med Chem; 2010 Mar; 45(3):1158-66. PubMed ID: 20045222
[TBL] [Abstract][Full Text] [Related]
12. The design and synthesis of purine inhibitors of CDK2. III.
Shum PW; Peet NP; Weintraub PM; Le TB; Zhao Z; Barbone F; Cashman B; Tsay J; Dwyer S; Loos PC; Powers EA; Kropp K; Wright PS; Bitonti A; Dumont J; Borcherding DR
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):1067-78. PubMed ID: 11562960
[TBL] [Abstract][Full Text] [Related]
13. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
Mettey Y; Gompel M; Thomas V; Garnier M; Leost M; Ceballos-Picot I; Noble M; Endicott J; Vierfond JM; Meijer L
J Med Chem; 2003 Jan; 46(2):222-36. PubMed ID: 12519061
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinase 2.
Marchetti F; Sayle KL; Bentley J; Clegg W; Curtin NJ; Endicott JA; Golding BT; Griffin RJ; Haggerty K; Harrington RW; Mesguiche V; Newell DR; Noble ME; Parsons RJ; Pratt DJ; Wang LZ; Hardcastle IR
Org Biomol Chem; 2007 May; 5(10):1577-85. PubMed ID: 17571187
[TBL] [Abstract][Full Text] [Related]
15. Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury.
Jaschke B; Milz S; Vogeser M; Michaelis C; Vorpahl M; Schömig A; Kastrati A; Wessely R
FASEB J; 2004 Aug; 18(11):1285-7. PubMed ID: 15180955
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship studies of flavopiridol analogues.
Murthi KK; Dubay M; McClure C; Brizuela L; Boisclair MD; Worland PJ; Mansuri MM; Pal K
Bioorg Med Chem Lett; 2000 May; 10(10):1037-41. PubMed ID: 10843211
[TBL] [Abstract][Full Text] [Related]
17. Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity.
Li W; Fan J; Bertino JR
Cancer Res; 2001 Mar; 61(6):2579-82. PubMed ID: 11289134
[TBL] [Abstract][Full Text] [Related]
18. Virtual screening studies to design potent CDK2-cyclin A inhibitors.
Vadivelan S; Sinha BN; Irudayam SJ; Jagarlapudi SA
J Chem Inf Model; 2007; 47(4):1526-35. PubMed ID: 17523616
[TBL] [Abstract][Full Text] [Related]
19. Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol.
de Azevedo WF; Canduri F; da Silveira NJ
Biochem Biophys Res Commun; 2002 Apr; 293(1):566-71. PubMed ID: 12054639
[TBL] [Abstract][Full Text] [Related]
20. Identification of a new series of flavopiridol-like structures as kinase inhibitors with high cytotoxic potency.
Ibrahim N; Bonnet P; Brion JD; Peyrat JF; Bignon J; Levaique H; Josselin B; Robert T; Colas P; Bach S; Messaoudi S; Alami M; Hamze A
Eur J Med Chem; 2020 Aug; 199():112355. PubMed ID: 32402934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
